fda glp-1 compounding enforcement news is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified 🚨 FDA Commissioner Signals Swift

Follow-up For both cohorts, we followed patients by using an on-treatment exposure definition, whereby we considered patients to be continuously exposed to the study drugs if consecutive prescriptions overlapped

GLP-1 safety trends and emerging side effects While gastrointestinal discomfort is the most common issue, new safety signals continue to emerge

Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids

Treatment should be provided within a specialist weight management service and is recommended for a maximum of 2 years

The U.K.'s National Institute for Health and Care Excellence, which creates guidance for the National Health Service, recommends two-year limits on the use of some weight loss medications, such as Wegovy